<DOC>
	<DOCNO>NCT01142011</DOCNO>
	<brief_summary>Hypothesis ; That inhibition plasma Blys monoclonal antibody Belimumab reduce survival lymphoplasmacytoid cell Waldenstrom Macroglobulinaemia ( WM ) , production monoclonal IgM , result reduction IgM paraprotein .</brief_summary>
	<brief_title>A Study Belimumab Treating Symptomatic Waldenstroms Macroglobulinaemia</brief_title>
	<detailed_description />
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>At least 18 year age . Diagnosis WM histologically confirm bone marrow biopsy . Detectable IgM paraprotein &gt; 5 g/L Less 3 line prior therapy WM Full blood count within 4 week prior screen show ANC &gt; 1.0 x109/l AND platelet count &gt; 50 x109/l Therapy indicate due development one following : 1. symptomatic anaemia 2. hyperviscosity symptom 3. rapidly rise paraprotein &gt; 25 % &gt; 5g/l 3 month 4. splenomegaly 5. bulky lymphadenopathy 6 . B symptom paraneoplastic phenomenon , , opinion investigator result progressive WM . Life expectancy &gt; 12 month ECOG &lt; 3 Able provide inform consent Ability understand requirement study , provide write informed consent , include consent use disclosure researchrelated health information , comply protocol procedure , include require study visit . Subjects child bear potential must agree use effective contraception throughout study 3 month last dose belimumab Prior therapy belimumab . Pregnant breast feeding Chemotherapy , immunotherapy biological therapy within 4 week enrolment . Therapeutic plasma exchange continue see section 3.1.4 . Creatinine clearance ( calculated CockcroftGault ) &lt; 60ml/min Bilirubin &gt; 2x ULN , ALT &gt; 2x ULN . History allergic anaphylactic reaction parenteral administration contrast agent , human murine proteins monoclonal antibody , history severe allergic reaction drug , food , insects require medical intervention , history hypersensitive triad ( 3 feature allergic rhinitis nasal polyp , asthma , aspirin sensitivity ) . Prior opportunistic infection include tuberculosis atypical mycobacterial infection , multidermatome Herpes Zoster Pneumocystis pneumonia invasive fungal infection ( include oral vaginal candidiasis superficial dermatophytes ) . Active infection hepatitis B , hepatitis C HIV historically positive test test positive screening HIV antibody , hepatitis B surface antigen , hepatitis C antibody . History organ transplant ( eg , heart , lung , kidney , liver ) hematopoietic stem cell/marrow transplant . Planned surgical procedure treatment period study history medical disease ( eg , cardiopulmonary ) , laboratory abnormality , condition , opinion principal investigator , make subject unsuitable study . Hospitalization treatment infection within 60 day Day 1 . Use parenteral ( IV IM ) antibiotic ( antibacterial , antiviral , antifungal , anti parasitic agent ) within 60 day Day 1 . Current drug alcohol abuse dependence , history drug alcohol abuse dependence within 364 day prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Waldenstroms</keyword>
	<keyword>Belimumab</keyword>
	<keyword>anti Blys</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>